Literature DB >> 22882882

Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening.

Pamela M McMahon1, Chung Yin Kong, Bruce E Johnson, Milton C Weinstein, Jane C Weeks, Angela C Tramontano, Lauren E Cipriano, Colleen Bouzan, G Scott Gazelle.   

Abstract

The natural history model underlying the MGH Lung Cancer Policy Model (LCPM) does not include the two-stage clonal expansion model employed in other CISNET lung models. We used the LCPM to predict numbers of U.S. lung cancer deaths for ages 30-84 between 1975 and 2000 under four scenarios as part of the comparative modeling analysis described in this issue. The LCPM is a comprehensive microsimulation model of lung cancer development, progression, detection, treatment, and survival. Individual-level patient histories are aggregated to estimate cohort or population-level outcomes. Lung cancer states are defined according to underlying disease variables, test results, and clinical events. By simulating detailed clinical procedures, the LCPM can predict benefits and harms attributable to a variety of patient management practices, including annual screening programs. Under the scenario of observed smoking patterns, predicted numbers of deaths from the calibrated LCPM were within 2% of observed over all years (1975-2000). The LCPM estimated that historical tobacco control policies achieved 28.6% (25.2% in men, 30.5% in women) of the potential reduction in U.S. lung cancer deaths had smoking had been eliminated entirely. The hypothetical adoption in 1975 of annual helical CT screening of all persons aged 55-74 with at least 30 pack-years of cigarette exposure to historical tobacco control would have yielded a proportion realized of 39.0% (42.0% in men, 33.3% in women). The adoption of annual screening would have prevented less than half as many lung cancer deaths as the elimination of cigarette smoking.
© 2011 Society for Risk Analysis.

Entities:  

Mesh:

Year:  2012        PMID: 22882882      PMCID: PMC3478757          DOI: 10.1111/j.1539-6924.2011.01652.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  15 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 2.  Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

Authors:  Robert W Carlson; Clifford A Hudis; Kathy I Pritchard
Journal:  J Natl Compr Canc Netw       Date:  2006-11       Impact factor: 11.908

3.  Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model.

Authors:  Rafael Meza; William D Hazelton; Graham A Colditz; Suresh H Moolgavkar
Journal:  Cancer Causes Control       Date:  2007-12-06       Impact factor: 2.506

4.  Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study.

Authors:  Pamela M McMahon; Chung Yin Kong; Bruce E Johnson; Milton C Weinstein; Jane C Weeks; Karen M Kuntz; Jo-Anne O Shepard; Stephen J Swensen; G Scott Gazelle
Journal:  Radiology       Date:  2008-05-05       Impact factor: 11.105

5.  Effect of screening and adjuvant therapy on mortality from breast cancer.

Authors:  Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

6.  Lung cancer death rates in lifelong nonsmokers.

Authors:  Michael J Thun; S Jane Henley; David Burns; Ahmedin Jemal; Thomas G Shanks; Eugenia E Calle
Journal:  J Natl Cancer Inst       Date:  2006-05-17       Impact factor: 13.506

7.  Multistage carcinogenesis and lung cancer mortality in three cohorts.

Authors:  William D Hazelton; Mark S Clements; Suresh H Moolgavkar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-05       Impact factor: 4.254

8.  Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period.

Authors:  Pamela M McMahon; Chung Yin Kong; Milton C Weinstein; Angela C Tramontano; Lauren E Cipriano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

9.  Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death.

Authors:  Marjorie A Rosenberg; Eric J Feuer; Binbing Yu; Jiafeng Sun; S Jane Henley; Thomas G Shanks; Christy M Anderson; Pamela M McMahon; Michael J Thun; David M Burns
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

10.  Mutation and cancer: a model for human carcinogenesis.

Authors:  S H Moolgavkar; A G Knudson
Journal:  J Natl Cancer Inst       Date:  1981-06       Impact factor: 13.506

View more
  19 in total

1.  Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model.

Authors:  Pari V Pandharipande; Curtis Heberle; Emily C Dowling; Chung Yin Kong; Angela Tramontano; Katherine E Perzan; William Brugge; Chin Hur
Journal:  Radiology       Date:  2014-11-12       Impact factor: 11.105

2.  Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models.

Authors:  William J McCarthy; Rafael Meza; Jihyoun Jeon; Suresh H Moolgavkar
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

3.  Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis.

Authors:  Kathryn P Lowry; G Scott Gazelle; Michael E Gilmore; Colden Johanson; Vidit Munshi; Sung Eun Choi; Angela C Tramontano; Chung Yin Kong; Pamela M McMahon
Journal:  Cancer       Date:  2015-02-03       Impact factor: 6.860

4.  Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities.

Authors:  Keith Sigel; Chung Yin Kong; Amanda Leiter; Minal Kale; Grace Mhango; Brian Huang; Michael K Gould; Juan Wisnivesky
Journal:  Lung Cancer       Date:  2022-05-30       Impact factor: 6.081

5.  Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period.

Authors:  Pamela M McMahon; Chung Yin Kong; Milton C Weinstein; Angela C Tramontano; Lauren E Cipriano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

6.  Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.

Authors:  Rafael Meza; Kevin ten Haaf; Chung Yin Kong; Ayca Erdogan; William C Black; Martin C Tammemagi; Sung Eun Choi; Jihyoun Jeon; Summer S Han; Vidit Munshi; Joost van Rosmalen; Paul Pinsky; Pamela M McMahon; Harry J de Koning; Eric J Feuer; William D Hazelton; Sylvia K Plevritis
Journal:  Cancer       Date:  2014-02-27       Impact factor: 6.860

7.  Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control.

Authors:  Theodore R Holford; Lauren Clark
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

8.  Chapter 13: CISNET lung models: comparison of model assumptions and model structures.

Authors:  Pamela M McMahon; William D Hazelton; Marek Kimmel; Lauren D Clarke
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

9.  Cost-effectiveness of follow-up of pulmonary nodules incidentally detected on cardiac computed tomographic angiography in patients with suspected coronary artery disease.

Authors:  Alexander Goehler; Pamela M McMahon; Heidi S Lumish; Carol C Wu; Vidit Munshi; Michael Gilmore; Jonathan H Chung; Brian B Ghoshhajra; Daniel Mark; Quynh A Truong; G Scott Gazelle; Udo Hoffmann
Journal:  Circulation       Date:  2014-07-11       Impact factor: 29.690

10.  Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities.

Authors:  Keith Sigel; Chung Yin Kong; Sadiq Rehmani; Susan Bates; Michael Gould; Kimberly Stone; Minal Kale; Yeun-Hee Park; Kristina Crothers; Faiz Bhora; Juan Wisnivesky
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.